1130 related articles for article (PubMed ID: 25516477)
1. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
Liu J; Xu Y; Hu Y; Wang G
Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.
Su X; Kong Y; Peng D
Clin Chim Acta; 2019 Nov; 498():30-37. PubMed ID: 31419414
[TBL] [Abstract][Full Text] [Related]
3. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
Tillman EJ; Rolph T
Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
Tucker B; Li H; Long X; Rye KA; Ong KL
Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
[TBL] [Abstract][Full Text] [Related]
5. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
[TBL] [Abstract][Full Text] [Related]
7.
Long X; Liu D; Gao Q; Ni J; Qian L; Ni Y; Fang Q; Jia W; Li H
Front Endocrinol (Lausanne); 2021; 12():773340. PubMed ID: 35035378
[TBL] [Abstract][Full Text] [Related]
8. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
Woolsey SJ; Beaton MD; Mansell SE; Leon-Ponte M; Yu J; Pin CL; Adams PC; Kim RB; Tirona RG
Mol Pharmacol; 2016 Oct; 90(4):437-46. PubMed ID: 27482056
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice.
Rusli F; Deelen J; Andriyani E; Boekschoten MV; Lute C; van den Akker EB; Müller M; Beekman M; Steegenga WT
Sci Rep; 2016 Jul; 6():30484. PubMed ID: 27470139
[TBL] [Abstract][Full Text] [Related]
10. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications.
Okubo H; Kushiyama A; Nakatsu Y; Yamamotoya T; Matsunaga Y; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Asano T
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30297626
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease.
Waluga M; Kukla M; Zorniak M; Kajor M; Liszka L; Dyaczynski M; Kowalski G; Zadlo D; Waluga E; Olczyk P; Buldak RJ; Berdowska A; Hartleb M
J Physiol Pharmacol; 2017 Jun; 68(3):363-374. PubMed ID: 28820393
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis and treatment of non-alcoholic fatty liver disease.
Altinbas A; Sowa JP; Hasenberg T; Canbay A
Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
[TBL] [Abstract][Full Text] [Related]
13. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease.
Smith BW; Adams LA
Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
[TBL] [Abstract][Full Text] [Related]
15. Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease.
Ashraf NU; Sheikh TA
Free Radic Res; 2015; 49(12):1405-18. PubMed ID: 26223319
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids and non-alcoholic fatty liver disease.
Woods CP; Hazlehurst JM; Tomlinson JW
J Steroid Biochem Mol Biol; 2015 Nov; 154():94-103. PubMed ID: 26241028
[TBL] [Abstract][Full Text] [Related]
17. Potential epigenetic mechanism in non-alcoholic Fatty liver disease.
Sun C; Fan JG; Qiao L
Int J Mol Sci; 2015 Mar; 16(3):5161-79. PubMed ID: 25751727
[TBL] [Abstract][Full Text] [Related]
18. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
[TBL] [Abstract][Full Text] [Related]
19. Reduced Oxidative Stress and Enhanced FGF21 Formation in Livers of Endurance-Exercised Rats with Diet-Induced NASH.
Henkel J; Buchheim-Dieckow K; Castro JP; Laeger T; Wardelmann K; Kleinridders A; Jöhrens K; Püschel GP
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31717358
[TBL] [Abstract][Full Text] [Related]
20. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Younossi ZM
Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
